

## Notice of Amendment to Code of Business Conduct and Ethics

On November 29, 2023, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), acting upon the recommendation of the Board’s Audit Committee (the “Audit Committee”), approved and adopted a revised Code of Business Conduct and Ethics (as revised, the “Code”), which amended, restated, and replaced the Company’s prior Code of Business Conduct and Ethics (the “Prior Code”). The Code applies to all directors, officers and employees of the Company. The Board reviews the Code periodically and amends it as appropriate.

The Code was revised to reflect current best practices, improve the ability of the Company to administer the Code and promote awareness of ethical issues that may be encountered in carrying out a director’s, officer’s or employee’s responsibilities. Changes to the Code include, among other things, updates and/or clarifications regarding (i) the Company’s policy relating to compliance with insider trading laws; (ii) the role of certain committees of the Board in approving certain transactions that could give rise to a conflict of interest and waivers of the Code; and (iii) protected whistleblower communications of possible violations of law or regulation to applicable governmental entities. The amendments also include other non-substantive revisions and administrative changes.

The Code does not materially change the responsibilities and obligations that previously applied to directors, officers and employees under the Prior Code. The adoption of the Code did not relate to, or result in, any waiver, explicit or implicit, of any provision of the Prior Code.

The foregoing description of the changes contained in the Code does not purport to be complete and is qualified in its entirety by reference to the full text of the Code, a copy of which is available on the Company’s website at [www.goodrx.com](http://www.goodrx.com) in the “Governance” section of the “Investors” page.